16th Annual Indy Hematology Review

Saturday, March 9, 2019
JW Marriott Indianapolis
10 S. West Street
Indianapolis, IN

Presented by:
Community Health Network
in collaboration with MD Anderson Cancer Network
A program of MD Anderson Cancer Center

Organized by:
Indy Hematology Education, Inc.

This Symposium is approved for 8.5 AMA PRA Category 1 Credit(s)™, 8.0 CNE contact hours, and 8.0 CPE contact hours by the Purdue University College of Pharmacy.
A full day of presentations by today’s leaders in Hematology and Hematologic Malignancies

Gain comprehensive clinical content that will immediately impact your practice. This full-day symposium features a series of didactic lectures presented by the nation’s top hematology experts from the Dana-Farber Cancer Institute, MD Anderson Cancer Center, Johns Hopkins School of Medicine, Lombardi Comprehensive Cancer Center, Mayo Clinic, and more!

The Indy Hematology Review brings together over 300 hematologists, oncologists, radiologists, physician assistants, oncology RN’s, nurse practitioners, pharmacists, medical students, and other allied health professionals. Stay current with a concise summary of the critical data presented at the American Society of Hematology (ASH) annual meeting. Examine significant scientific updates in clinical hematologic research, learn how these updates directly affect the study and practice of hematology, and discover how new research can be translated into new patient care strategies.

Dive deeper into new advances and targeted treatments for:
- Multiple Myeloma
- Waldenström's Macroglobulinemia
- Benign and Non-Benign Hematology
- Indolent Lymphomas and Hodgkin's Lymphoma
- Acute Lymphoblastic Leukemia
- Chronic and Acute Myeloid Leukemias
- Myeloproliferative Neoplasms
- Myelodysplastic Syndrome
- Hematopoietic Stem Cell Transplantation

Visit the Exhibit Hall
Visit the exhibit hall to experience a showcase of the latest technology and research in hematology. The exhibit hall offers an opportunity to learn about a wide range of products and services offered by pharmaceutical companies, medical suppliers, biotechnology companies, healthcare systems, and research-based companies. Stop in for a beverage and snack at the “Physicians’ Lounge” as you visit exhibitors.
Ruemu Birhiray, MD (Chair)
CEO, Indy Hematology Education, Inc.
Partner and Vice President, Hematology Oncology of Indiana, PC

Michael C. Wiemann, MD, FACP (Co-Chair)
President, Providence Hospital
Executive Vice President West Region, St. John Providence Health System

Donna Birhiray, OTR, MBA
Indy Hematology Education, Inc.
Treasurer

Thalia Hammond
Indy Hematology Education, Inc.

Jennifer Wheeler-Terry, JD
Wabash College

Debbie Locklear
Meeting Services Unlimited, Inc.
President

Tina Machina, CMP
Meeting Services Unlimited, Inc.
Director of Conventions

INDY HEMATOLOGY EDUCATION, INC.
Indy Hematology Education, Inc. is a 501(c), non-profit corporation, incorporated on February 15, 2010, in the State of Indiana, with the following purposes:

(a) Raise awareness and provide education regarding hematology and oncology diseases and disorders

(b) To encourage youth to pursue careers in hematology and oncology and

(c) To connect individuals suffering from or affected by hematology and oncology diseases and disorders to organizations, programs, and service providers.

Register online: www.indyhematologyreview.com
7:00 AM - 2:30 PM – Registration

7:00 AM - 5:00 PM – Exhibit displays

7:30 AM – Breakfast: Product Theaters

8:30 AM – State of the Art: 2019 Emerging Therapies in Hematologic Malignancies
   Ruemu E. Birhiray, MD – Chair
   CEO, Indy Hematology Education, Inc.
   Associate Professor of Clinical Medicine,
   Marian University of Osteopathic Medicine
   Partner and Vice President, Hematology Oncology of Indiana, PC (Indianapolis, IN)

9:00 AM – Multiple Myeloma: Changing and Emerging Treatment Paradigms
   Kenneth Anderson, MD
   Kraft Family Professor of Medicine, Harvard Medical School
   Program Director of the Lebow Institute for Myeloma Therapeutics and
   Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (Boston, MA)

9:30 AM – Waldenström’s Macroglobulinemia: Beyond the Diagnosis
   Steven Treon, MD, MA, PhD
   Associate Professor of Medicine, Harvard Medical School
   Senior Attending Physician for Medical Oncology at DFCI and Brigham & Women’s Hospital
   Director of the Bing Center for Waldenström’s Macroglobulinemia
   Dana-Farber Cancer Institute (Boston, MA)

10:00 AM – Chronic Lymphocytic Leukemia: How to Treat in 2019
   Michael Keating, MB, BS
   Clinical Professor of Medicine, Department of Leukemia
   Division of Cancer Medicine
   The University of Texas MD Anderson Cancer Center (Houston, TX)

10:45 AM – Indolent Lymphomas and Hodgkin’s Lymphoma: Achieving Curability
   Bruce Cheson, MD, FACP, FAAS, FACSO
   Deputy Chief of Division of Hematology and Oncology
   Head of Hematology and Professor of Medicine
   Lombardi Comprehensive Cancer Center
   MedStar Georgetown University Hospital (Washington, DC)

11:15 AM – Aggressive B and T Cell Lymphomas: Chemotherapy, Antibodies, Immunotherapy
   John Leonard, MD
   Attending Physician, New York-Presbyterian Hospital
   Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
   Associate Dean of Clinical Research and Interim Chair of Department of Medicine
   Weill Cornell Medical College (New York, NY)

11:45 AM – Not so Benign Hematology: Complementopathies and Aplastic Anemia
   Robert Brodsky, MD
   Director of Division of Hematology
   Johns Hopkins Family Professor of Medicine and Oncology
   Johns Hopkins University School of Medicine (Baltimore, MD)

12:15 PM – Benign Hematology: Cytopenias, Clotting, and Bleeding
   Craig Kessler, MD
   Professor of Medicine and Pathology
   Director of Clinical Coagulation Laboratory in Division of Laboratory Medicine
   Lombardi Comprehensive Cancer Center
   MedStar Georgetown University Hospital (Washington, DC)

2:00 PM – T. HOWARD LEE KEYNOTE LECTURE:
   Emerging Targeted Therapies for Follicular Lymphomas: A Future Without Chemotherapy
   Pier Zinzani, MD, PhD
   Professor of Hematology, Head of Lymphoma Group
   Institute of Hematology “L. e A. Seràgnoli” University of Bologna (Bologna, Italy)

3:00 PM – Challenging Cases Presentation
   Michael C. Wiemann, MD – Co-Chair
   President of Providence Hospital Executive Vice President West Region, St. John Providence Health System (Warren, MI)

3:05 PM – Chronic Myeloid Leukemia: Targeted Therapy in 2019
   Richard Larson, MD
   Professor of Medicine in Section of Hematology/Oncology,
   Director of Hematologic Malignancies Clinical Research Program
   The University of Chicago Comprehensive Cancer Center (Chicago, IL)

3:35 PM – Myeloproliferative Neoplasms: Genetic Prognostication and Current Treatment
   Ayalew T. Tcheghiri, MD, PhD
   Professor of Hematology and Internal Medicine
   Mayo Clinic (Rochester, MN)

4:05 PM – Practical Considerations in the Treatment of Polycythemia Vera and Myelofibrosis
   Angela Fleischman, MD, PhD
   Assistant Professor, Department of Medicine Division of Hematology/Oncology
   University of California, Irvine Health (Irvine, CA)

4:35 PM – Break with Q & A

10:30 AM – Break with Q & A
4:45 PM – Acute Lymphoblastic Leukemia: Emerging and Targeted Therapies
Hagop Kantarjian, MD
Samsung Distinguished University Chair in Cancer Medicine, Associate Vice President for Global Academic Programs, Professor and Department Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center (Houston, TX)

5:45 PM – Myelodysplastic Syndrome; How Much Further Do We Have To Travel?
Richard Stone, MD
Attending Physician, Brigham and Women’s Hospital Professor of Medicine, Harvard Medical School Director, Adult Leukemia Program Dana-Farber Cancer Institute (Boston, MA)

6:15 PM – Hematopoietic Stem Cell Transplantation: How I Treat and When I Transplant in 2019
Richard Childs, MD, RADM, USPHS
Senior Investigator for Laboratory of Transplantation Immunotherapy Clinical Director, National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (Bethesda, MD)

7:00 PM – 8:30 PM – Challenging Cases in Lymphoproliferative and Plasma Cell Disorders / Interactive Meeting with the Professors / Reception
Paul Richardson, MD
R.J. Corman Professor of Medicine, Harvard Medical School Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute (Boston, MA)

5:15 PM – Acute Myeloid Leukemias: Treatment Options in 2019
Martin Tallman, MD
Chief of Leukemia Service and Professor of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College (New York, NY)

6:45 PM – Wrap Up and Adjourn

10:00 AM – Break with Q & A

10:15 AM – Aggressive Lymphomas
Sonali Smith, MD

10:35 AM – Chronic Leukemias
Michael Keating, MB, BS

10:55 AM – Break with Q & A

11:10 AM – Myeloproliferative Neoplasms
Ayalew Tefferi, MD, PhD

11:30 AM – Recognition and Management of Toxicities of Oral Therapeutics in Hematologic Malignancies
Michelle Wright Mast, FNP-BC
Nurse Practitioner, Hematology/Oncology, St. Vincent Medical Group (Indianapolis, IN)

12:00 PM – Emesis and Nutritional Strategies for Hematologic Malignancies
Paul Richardson, MD

12:30 PM – Multiple Myeloma
Paul Richardson, MD

12:50 PM – Break with Q & A

1:00 PM – Lunch: Product Theaters

2:00 PM – Adjourn and join General Session for T. Howard Lee Lecture
## REGISTRATION

To register online, go to [indyhematologyreview.com](http://indyhematologyreview.com) and click on “Register.”

### Early Bird Registration: ends February 1, 2019
- Early Bird Physicians: $185.00
- Early Bird Physicians + CME Fee: $210.00
- Early Bird Allied Health & Nurses: $110.00
- Early Bird Allied Health & Nurses + CME Fee: $135.00
- Early Bird Nurse Practitioners & Pharmacists: $135.00
- Early Bird Nurse Practitioners & Pharmacists + CPE Fee: $160.00
- Industry & Exhibitors: $360.00

### Standard Registration: after February 1, 2019
- Physicians: $235.00
- Physicians + CME Fee: $260.00
- Allied Health & Nurses: $160.00
- Allied Health & Nurses + CME Fee: $185.00
- Nurse Practitioners & Pharmacists: $185.00
- Nurse Practitioners & Pharmacists + CPE Fee: $210.00
- Industry & Exhibitors: $360.00
- Student/Fellow Scholarship* (Limited Number): $25.00
- Nurse Scholarship* (Limited Number): $25.00

*A limited number of scholarships are available on a first-come, first-served basis.

If you are registering clinicians for your office, fill in the attendee’s full name and e-mail address so the post-event survey and continuing education credits are e-mailed to the attendee.

### REFUND POLICY

Request a registration cancellation refund on or before February 22, 2019, to receive a Full Refund. After February 22, there is NO REFUND.

### HOTEL RESERVATIONS

Make your reservation online at [indyhematologyreview.com](http://indyhematologyreview.com) and click on “Hotel/Parking.” You may also call the JW Marriott Indianapolis directly at 317-860-5800 or toll free at 1-888-236-2427. Mention “Indy Hematology Review” for the discounted group rate of $192 plus tax (currently 17%). Access to the block of discounted rooms will close on Friday, February 15, 2019. Make your reservation early!

### PARKING

Parking is available at the JW Marriott Indianapolis. 24-hour parking rates are currently: $44.00 on-site parking; $49.00 valet. *Rates are subject to change without notice.*

Self-parking is also available at the Government Center Washington St. Parking Facility, 401 West Washington Street. First Hour: $15.00; Daily Maximum: $25.00

### QUESTIONS?

Please contact 317-841-7171, Indyhr@conventionmanagers.com.
CONTINUING EDUCATION INFORMATION

PHYSICIANS

LEARNING OBJECTIVES
At the completion of this activity, participants should be able to:
1. Discuss new emerging hematology therapies in general and for chronic Myeloid Leukemia, acute Promyelocytic and Myeloid Leukemia, and Myeloproliferative neoplasms.
2. Evaluate molecular diagnosis, targeted therapies, and resistance mechanisms of Waldenström’s Macroglobulinemia to assist in disease recognition.
3. Discuss the advancement of immune checkpoint inhibitors within hematologic malignancies and updated treatment paradigms presented at the American Society of Hematology meeting in San Diego, CA in December 2018.
5. Review the advancement in benign hematology research.

CME ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and Indy Hematology Education, Inc. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

DESIGNATION STATEMENT
Purdue University College of Pharmacy designates this live activity for a maximum of 8.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE STATEMENT
All faculty, staff, and reviewers involved in the planning, review, or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, staff, and reviewers of Indy Hematology Education, Inc. and Purdue University College of Pharmacy have no relationships to disclose.

NOTE: While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.

NURSES

CNE ACCREDITATION STATEMENT
Purdue University Continuing Nursing Education is accredited as a provider of continuing nursing education with distinction by the American Nurses Credentialing Center’s Commission on Accreditation.

This program is approved for 8.0 contact hours.

PHARMACISTS

CPE ACCREDITATION STATEMENT
Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge based, continuing education activity of Purdue University, an equal access/equal opportunity institution.

Universal Activity Number (UAN): 0018-9999-19-001-L01-P
This program is approved for 8.0 contact hours (0.8 CEU's).

PHARMACY LEARNING OBJECTIVES
At the completion of this activity, participants should be able to:
1. Discuss new emerging hematology therapies in general and for chronic Myeloid Leukemia, acute Promyelocytic and Myeloid Leukemia, and Myeloproliferative neoplasms.
2. Evaluate molecular diagnosis, targeted therapies, and resistance mechanisms of Waldenström’s Macroglobulinemia to assist in disease recognition.
3. Discuss the advancement of immune checkpoint inhibitors within hematologic malignancies and updated treatment paradigms presented at the American Society of Hematology meeting in San Diego, CA in December 2018.
5. Review the advancement in benign hematology research.

NOTE: While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.
16th Annual Indy Hematology Review
Saturday, March 9, 2019 | 7:00 am – 8:30 pm

Presented by:

Community Health Network in collaboration with MD Anderson Cancer Network

JW Marriott Indianapolis
10 S. West Street
Indianapolis, IN